Paolo G.
- Country
- Italy
- Department
- Chronic Inflammatory Bowel Diseases
Research Overview
- Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
- Efficacy and Safety of Obefazimod (ABX464) in Adults with Moderately to Severely Active Ulcerative Colitis: A Randomized Placebo‑Controlled Phase III Study
Data & Insights
Has run more than one trial at 54 of 138 partner sites.
Specializations
Inflammatory Bowel Disease Treatment
The investigator specializes in developing therapeutic approaches for inflammatory bowel diseases, with particular focus on both ulcerative colitis and Crohn's disease.
- Moderately to severely active UC management
- Crohn's disease therapeutic interventions
- Novel treatment pathways investigation
Clinical research focuses on evaluating various therapeutic agents for achieving clinical remission and endoscopic response in IBD patients.
Therapeutic Innovation
Conducts research on multiple innovative compounds including risankizumab, guselkumab, and obefazimod for inflammatory bowel conditions.
- Advanced therapy development
- Long-term treatment efficacy
- Treatment resistance solutions
Evaluates therapeutic responses in patients who have shown inadequate response to conventional treatments.
Clinical Outcomes Research
Focuses on investigating endoscopic improvement and clinical remission in gastrointestinal disorders.
- Endoscopic response assessment
- Symptomatic remission evaluation
- Long-term safety monitoring
Examines both short-term therapeutic efficacy and extended treatment outcomes in inflammatory bowel conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.